Basic Femara Information

• INN (International Nonproprietary Name): Letrozole.
• Brand Names Available In United Kingdom: Femara, 2.5 mg tablets, supplied in packs of 14 or 30 tablets.
• ATC Code: L02BG04 — Aromatase Inhibitors.
• Forms & Dosages: Oral film-coated tablets 2.5 mg; typical packaging includes blisters or bottles (7, 10, 14, 28, 30 or 100 tablets).
• Manufacturers In United Kingdom: Novartis Pharma AG (originator) and licensed generic producers such as Sandoz among other authorised suppliers.
• Registration Status In United Kingdom: Femara is authorised and marketed in the UK as a 2.5 mg tablet formulation and is approved in Europe for hormone receptor–positive breast cancer in postmenopausal women.
• OTC / Rx Classification: Prescription Only (Rx). Letrozole/Femara is never available over the counter.

Everyday Use & Best Practices

Morning Vs Evening Dosing

Patients often ask whether to take Femara in the morning or evening.

The standard adult dose is 2.5 mg once daily, taken orally.

Choose a time you can reliably repeat every day to reduce missed doses.

Many UK patients take Femara in the morning as part of a pill‑box routine, alongside other daily medicines.

Some patients prefer an evening dose if hot flushes or sleep disturbance occur at night.

If a dose is missed, take it as soon as you remember unless it is nearly time for the next dose, in which case skip the missed dose.

Never double the dose to make up for a missed tablet.

Taking With Or Without Meals (UK Diet Habits)

• Letrozole can be taken with or without food, so pair it with a regular UK breakfast habit such as toast and tea or with the evening meal.
• When taking multiple medicines, place Femara with other daily tablets in a labelled dosette box but keep the original blister in a dry place to protect from moisture.
• Store tablets below 30°C and avoid leaving blisters in bathrooms or hot cars during summer trips.
• For holiday plans or late shifts, link the dose to a fixed daily activity (for example, morning tea) to preserve routine.

Missed Dose Checklist

• If you remember soon after the missed time, take the tablet straight away.
• If it is almost time for the next dose, skip the missed tablet and take the next as scheduled.
• Do not take two tablets on the same day to make up for a missed dose.

Safety Priorities

Who Should Avoid It (MHRA Warnings)

Femara is prescription-only and is contraindicated in pre‑menopausal women.

Pregnancy and breastfeeding are absolute contraindications because of teratogenic risk.

Do not use letrozole for ovulation induction without specialist supervision.

Tell your GP or oncology team if your menopausal status is uncertain.

If you have known hypersensitivity to letrozole or any tablet excipients, stop treatment and seek immediate care for severe allergic symptoms.

Activities To Limit (Driving, Work Safety)

Letrozole can cause fatigue, dizziness or visual disturbance in some people.

Until you know how Femara affects you, avoid driving heavy machinery or safety‑critical work.

If joint pain or musculoskeletal symptoms affect mobility, contact occupational health or your GP to request workplace adjustments.

Keep a symptom diary noting fatigue, dizziness and pain to discuss at clinic reviews.

Contraindication Checklist

• Pre‑menopausal women — do not use.
• Pregnancy and breastfeeding — do not use.
• Known allergy to letrozole or excipients — stop and seek help.

Dosage & Adjustments

General Regimen (NHS Guidance)

The standard regimen for adults is letrozole 2.5 mg once daily by mouth.

This dosing applies for adjuvant therapy, first‑line treatment of advanced or metastatic disease, and extended adjuvant therapy.

Extended adjuvant therapy commonly totals five years and may be longer as advised by an oncologist.

Femara is prescription-only and typically dispensed in 14 or 30 tablet packs in the UK.

Special Cases (Elderly, Comorbidities)

Monitoring Checklist

• No routine dose adjustment usually required for the elderly.
• Mild–moderate hepatic or renal impairment: standard dosing generally applies.
• Severe liver disease or creatinine clearance below 10 ml/min requires specialist review.
• Pre‑existing osteoporosis needs baseline DEXA and active bone protection (calcium, vitamin D, and bisphosphonates if indicated).
• Not indicated for children.

User Testimonials

Positive Reports From UK Patients

"My oncology nurse explained everything and the once‑daily tablet fitted easily into my morning routine," is a typical anonymised comment from UK forums.

Many patients report that Femara provides effective control of hormone‑sensitive disease when it is indicated by the oncology team.

Patients appreciate the convenience of 2.5 mg once‑daily tablets and the availability in 14 or 30 tablet blister packs.

Some describe hot flushes that are manageable with lifestyle measures or timing adjustments.

Common Challenges (Patient.info, NHS Forums)

• Arthralgia or joint pain that can limit exercise and daily activities.
• Ongoing fatigue that may take weeks to settle after starting treatment.
• Concerns about bone density and the need for DEXA scans and bone‑protective therapy.
• Noted changes in cholesterol in some patients, prompting dietary advice from a dietitian.

Pros

• Once‑daily dosing is simple.
• Effective for postmenopausal, hormone receptor–positive breast cancer when prescribed appropriately.
• Wide availability of generics reduces cost for private prescriptions.

Cons

• Joint pain, fatigue and bone loss are common concerns.
• Prescription charge complexity in England compared with free prescriptions in Scotland, Wales and Northern Ireland can cause confusion.

Buying Guide

Pharmacy Sources (Boots, LloydsPharmacy, Superdrug)

Femara (letrozole 2.5 mg) is prescription-only and dispensed by community pharmacies including Boots, LloydsPharmacy and Superdrug, and by hospital pharmacies.

Patients usually collect from local branches or use NHS repeat dispensing arrangements where available.

Reputable online pharmacies can deliver on valid prescriptions; always use MHRA‑regulated retailers and check packaging for 2.5 mg film‑coated tablets in blister packs.

In our online pharmacy, femara is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Price Comparison (NHS Prescription Charge Vs Private)

Safe Online Purchase Checklist

• Use only MHRA‑regulated online pharmacies.
• Check that the product is 2.5 mg film‑coated tablets in blister packs.
• Request a prescription cost estimate from the pharmacist before ordering privately.
• Consider hospital supply if you are under an oncology clinic and eligible for clinic dispensing.

What’s Inside & How It Works

Ingredients Overview

• Active Ingredient: letrozole (INN), 2.5 mg per tablet.
• Formulation: oral film‑coated tablets only; no injectable or topical forms are authorised for patients.
• Excipients vary by manufacturer; check the patient leaflet for allergy information.
• Storage: keep in original blister, protect from moisture and store below 30°C.

Mechanism Basics Explained Simply

Letrozole blocks the aromatase enzyme that converts androgens to oestrogens in postmenopausal women.

Lowered oestrogen levels reduce stimulation of oestrogen‑dependent (hormone receptor‑positive) breast cancer cells.

The result is reduced tumour growth signal and clinical benefit in the licensed indications.

Main Indications

Approved Uses (MHRA Listing)

Letrozole is licensed for hormone receptor‑positive breast cancer in postmenopausal women.

Approved settings include adjuvant treatment for early breast cancer, first‑line therapy for advanced or metastatic disease, and extended adjuvant therapy commonly up to five years.

Typical adult dose across these indications is 2.5 mg once daily.

Off‑Label Uses In UK Clinics

Any off‑label prescribing should be discussed in detail with the treating clinician and documented with appropriate consent and monitoring.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

Letrozole has no major food interactions and can be taken with or without meals.

Advise moderation of alcohol because it can worsen fatigue and hot flushes.

Caffeine from tea or coffee may aggravate palpitations or sleep disturbance and could indirectly worsen side effects such as anxiety or insomnia.

Drug Conflicts (MHRA Yellow Card Reports)

Letrozole is metabolised by hepatic pathways and may be affected by potent CYP450 inducers or inhibitors.

Flag concomitant drugs such as some anticonvulsants, strong CYP inducers or inhibitors, and review statins and anticoagulants with the prescriber as needed.

Report suspected interactions or adverse drug reactions via the MHRA Yellow Card scheme.

Latest Evidence & Insights

Key UK & EU Studies 2022–2025

• Recent trials and reviews reaffirm letrozole’s benefit in adjuvant treatment for postmenopausal, hormone receptor‑positive breast cancer.
• Evidence supports extended therapy to five years and, in selected patients, longer durations when balanced against side‑effect burden.
• Studies consistently highlight bone density loss risk with aromatase inhibitors and recommend baseline and interval DEXA scanning.
• Comparative analyses place letrozole alongside anastrozole and exemestane with broadly similar efficacy; choice is often guided by tolerability and comorbidities.

Alternative Choices

NHS Prescribing Alternatives With Pros/Cons Checklist

Alternatives available on the NHS include other aromatase inhibitors such as anastrozole and exemestane, and the SERM tamoxifen in appropriate contexts.

• Anastrozole — similar efficacy to letrozole; consider if tolerability differs.
• Exemestane — steroidal aromatase inactivator; may be chosen for individual patient characteristics.
• Tamoxifen — used in pre‑ or perimenopausal women and where bone density preservation is a priority.

Practical Switching Advice

Switching between aromatase inhibitors is arranged by oncology teams and documented in shared‑care letters.

A washout period is not routinely required unless specified by a specialist.

After a switch, monitor symptoms closely and consider repeat DEXA scanning if bone risk is present.

Ensure clear prescription documentation to avoid gaps in supply at community pharmacies.

Regulation Snapshot

MHRA Approval & NHS Prescribing Framework

Letrozole (Femara) is authorised in the UK and used within MHRA and NHS oncology frameworks for postmenopausal hormone receptor‑positive breast cancer.

Specialist units normally initiate therapy with possible shared‑care follow‑up arranged with GPs.

The product is prescription‑only and supplied as 2.5 mg film‑coated tablets.

International Regulatory Notes (Quick)

Letrozole is approved by major regulators including EMA and FDA and is available in many global markets under Femara and various generic names.

Generics from manufacturers such as Sandoz are available in the UK; always check product labelling and ensure authorised supply chains.

Patient Rights Checklist

• Ask for written information and the patient leaflet when the medicine is dispensed.
• Expect explanation of why letrozole is being prescribed and what monitoring will be done.
• Request a shared‑care letter or care plan summarising who manages prescriptions and monitoring.

FAQ Section

Common UK Patient Questions

1. Can I drive on Femara? — Usually yes; avoid driving until you know whether fatigue or dizziness occurs.
2. Will it affect my bones? — Aromatase inhibitors can reduce bone density; baseline DEXA and calcium/vitamin D and possible bisphosphonate therapy may be advised.
3. Can I take it with other medicines? — Check with your pharmacist or GP about potential CYP interactions; report suspected problems via the MHRA Yellow Card.
4. Is it free on the NHS? — Prescription charges apply in England unless you are exempt; prescriptions are free in Scotland, Wales and Northern Ireland.

How To Report Side Effects And Where To Get Support

Report adverse effects to your oncology team and consider submitting a report to the MHRA Yellow Card scheme for national pharmacovigilance.

For emotional or practical support, contact NHS Macmillan services and local cancer support centres.

Your local community pharmacist can provide advice about drug interactions, side‑effect management and where to seek urgent care.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Pharmacists should confirm the indication and menopausal status and check for contraindications such as pregnancy or pre‑menopausal status.

Review concomitant medicines for interactions and advise on bone health monitoring, including DEXA scans and supplements where appropriate.

Provide the patient leaflet and reinforce missed‑dose and overdose guidance: take a missed dose when remembered unless it is almost time for the next dose, and in the event of overdose provide supportive care and monitoring.

NHS Patient Support Advice

Advise patients on lifestyle measures to protect bone and cardiovascular health: regular weight‑bearing exercise, smoking cessation, a balanced diet and alcohol moderation.

Encourage patients to record new symptoms such as arthralgia, persistent fatigue or mood changes and to contact their oncology team or GP promptly for concerning issues.

Recommend reporting adverse effects to the MHRA Yellow Card scheme and using local support groups for practical and emotional help.

Delivery Across United Kingdom

Final Notes

Femara (letrozole 2.5 mg) is a well-established aromatase inhibitor used in postmenopausal hormone receptor‑positive breast cancer when prescribed by a clinician.

Always follow the oncology team's instruction on duration and monitoring, and keep a record of symptoms between clinic visits.

Pharmacists are a good first point of contact for queries about dosing routines, storage and minor side‑effect management.

For urgent or severe reactions, seek immediate medical attention or contact your oncology unit without delay.